PHS
ACAD icon

PFM Health Sciences’s Acadia Pharmaceuticals ACAD Stock Holding History

PFM Health Sciences’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-602,100
Closed -$14.7M – 86
2021
Q2 		$14.7M Buy
+602,100
New +$13.6M 0.46% 57
2021
Q1 		– Sell
-270,000
Closed -$14.4M – 87
2020
Q4 		$14.4M Buy
+270,000
New +$13.4M 0.51% 63

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PFM Health Sciences's ACAD Position: Q3 2022 in Review

PFM Health Sciences sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 384,995 shares — an estimated $5.42M sold.

PFM Health Sciences first reported a position in ACAD in Q1 2014 and held it in 10 quarters. The position peaked at $68.5M in Q2 2021. 222 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

  • PFM Health Sciences reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • PFM Health Sciences sold 384,995 Acadia Pharmaceuticals shares in Q3 2022, an estimated $5.42M.
  • PFM Health Sciences first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 10 quarters.
  • PFM Health Sciences's Acadia Pharmaceuticals position peaked at $68.5M in Q2 2021.
  • 222 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on PFM Health Sciences's 13F filing for Q3 2022, filed 14 Nov 2022.